在患有长期心房高频发作≥24小时的患者中使用edoxaban的抗凝药
Nina Becher1,2, Tobias Toennis1,2, Emanuele Bertaglia3
1Department of Cardiology, University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, Hamburg 20246, Germany.
European heart journal
|November 13, 2023
概括
这项研究发现长期心房高频发作 (AHREs) 和抗凝剂在预防中风方面的有效性之间没有相互作用. 需要进一步的研究来确定患有长期AHREs的高风险患者.
科学领域:
- 心脏病学 心脏病学
- 电子生理学 电子生理学
- 临床试验 临床试验
背景情况:
- 患有长期心房高频发作 (AHREs) 和中风风险因素的患者经常接受抗凝药.
- 在这个特定的患者群体中,抗凝剂与不使用抗凝剂的比较疗效和安全性尚未确定.
研究的目的:
- 研究心房高频发作 (AHREs) 持续时间与抗凝治疗的疗效和安全性之间的相互作用.
- 在患有AHREs和中风风险因素的患者中,评估edoxaban与安慰剂的对比.
主要方法:
- 对NOAH-AFNET 6试验的二次分析检查了患有AHREs和中风风险因素的患者.
- 这项研究将抗凝药与安慰剂进行了比较,评估了中风,全身栓塞或心血管死亡的主要结果,以及重大出血或死亡的安全结果.
- 分析了AHRE持续时间作为基线特征和连续参数.
主要成果:
- 在AHREs≥24小时的患者中,与安慰剂相比,抗凝药与疗效或安全没有显著的相互作用.
- 主要结局发生在4.3%/患者-年与抗凝药相比6.9%/患者-年与安慰剂对于那些与AHREs≥24小时.
- 与较短AHREs患者相比,AHREs≥24小时的患者患心电图诊断的心房的发病率更高.
结论:
- 这项分析表明,在设备检测到的AHRE和中风风险因素的患者中,AHRE持续时间和抗凝治疗之间没有相互作用.
- 需要进一步的研究,以准确识别患有长期AHREs的患者,这些患者患中风的风险很高.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
719
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
719
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
847
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
847


